Thalidomide-O-amido-C4-NH2
Code | Size | Price |
---|
TAR-T17818-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T17818-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6) is a synthesized ligand-linker conjugate that combines a Thalidomide-based cereblon ligand with a linker. It functions as an E3 ligase ligand-linker conjugate and finds applications in the synthesis of PROTACs[1].
CAS:
1799711-24-2
Molecular Weight:
402.4
Purity:
0.98
SMILES:
O=C(NCCCCN)COC1=CC=CC=2C(=O)N(C(=O)C12)C3C(=O)NC(=O)CC3
References
Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins withPicomolar Cellular Potencies and Capable of Achieving Tumor Regression.J Med Chem. 2018 Jan 25;61(2):462-481.
James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO 2017024317 A2.